Vyepti clinical trials?

Here’s a concise overview of the key clinical trials for Vyepti (eptinezumab-jjmr), the IV CGRP preventive for adults with migraine.

What Vyepti is
- A monoclonal antibody against CGRP, given by IV infusion.
- Dosing: 300 mg every 12 weeks (the label also studied 100 mg and 300 mg in trials).
- Approved for preventive treatment of migraine in adults.

Major pivotal trials
- PROMISE-1 (episodic migraine)
- Design: Randomized, double-blind, placebo-controlled; eptinezumab 100 mg and 300 mg vs placebo.
- Primary outcomes: Change in monthly migraine days (MMDs) from baseline to Week 12; proportion achieving ≥50% reduction in MMDs.
- Key findings: Both dose levels reduced MMDs versus placebo; higher responder rates with 300 mg; onset of benefit observed relatively early (during the first weeks after infusion); safety profile similar to placebo.
- Safety: Common adverse events were generally mild (e.g., nasopharyngitis, upper respiratory tract infections); low risk of serious adverse events; low incidence of anti-drug antibodies.

- PROMISE-2 (chronic migraine)
- Design: Randomized, double-blind, placebo-controlled; same dosing arms as PROMISE-1.
- Primary outcomes: Same as PROMISE-1 (MMD change, ≥50% responders).
- Key findings: Significant reductions in MMDs with eptinezumab 100 mg and 300 mg versus placebo; 300 mg generally showed greater efficacy; benefits appeared quickly after infusion and were sustained through Week 12.
- Safety: Similar profile to PROMISE-1; generally well tolerated; anti-drug antibody rates remained low.

Long-term and additional data
- Open-label extension (OLE) studies
- Purpose: Assess safety and sustained efficacy over longer periods.
- Findings: Efficacy and safety maintained or continued to improve with longer exposure; supports long-term use every 12 weeks.
- Real-world and secondary analyses
- Generally supportive of the pivotal trial outcomes: meaningful reductions in migraine days and good tolerability with quarterly IV dosing.

What this means in practice
- For adults with migraine, Vyepti 300 mg IV every 12 weeks has demonstrated:
- Significant reductions in monthly migraine days in both episodic and chronic migraine populations.
- Rapid onset of benefit after the first infusion, with continued improvement over the initial weeks.
- A favorable safety profile, with common adverse events similar to placebo and low immunogenicity.
- It is a preventive therapy (not for acute treatment of migraine attacks).

If you’d like, I can:
- Pull specific numbers (e.g., exact reductions in MMDs and responder rates) from PROMISE-1 and PROMISE-2.
- Summarize safety signals in more detail (special populations, pregnancy considerations, cardiovascular safety).
- Look up the latest post-marketing or real-world data.

Would you prefer a deeper dive into the numbers from PROMISE-1/2 or a focus on safety and long-term use?